Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

The recent arrival of CDK4/6 inhibitor agents, with an approximate doubling of progression-free survival (PFS) associated with their use in hormone receptor-positive, HER2-negative advanced breast cancer (BC), has radically changed the approach to managing this disease. However, resistance to CDK4/6...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Oncol
Hlavní autoři: McCartney, Amelia, Migliaccio, Ilenia, Bonechi, Martina, Biagioni, Chiara, Romagnoli, Dario, De Luca, Francesca, Galardi, Francesca, Risi, Emanuela, De Santo, Irene, Benelli, Matteo, Malorni, Luca, Di Leo, Angelo
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2019
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6664013/
https://ncbi.nlm.nih.gov/pubmed/31396487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00666
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky